Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
about
H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccinesCross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particlePre-existing immunity against swine-origin H1N1 influenza viruses in the general human populationRole of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoproteinCurrent advancements and potential strategies in the development of MERS-CoV vaccinesPreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineInterference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodiesSecretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potentialEpitope specific T-cell responses against influenza A in a healthy population.Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infectionImmunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.Development of stable influenza vaccine powder formulations: challenges and possibilitiesDevelopment of mucosal adjuvants for intranasal vaccine for H5N1 influenza virusesGastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.Microneedle and mucosal delivery of influenza vaccines.Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.Intranasal antibody prophylaxis for protection against viral disease.Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus.Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigsRole of systemic and mucosal immune responses in reciprocal protection against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infectionEfficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine.Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysisMucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection.Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant womenA novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in agingInactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin.Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusPoliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodiesHeterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoireOral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with infRoles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouseMechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgGImmunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium.Sublingual vaccination with influenza virus protects mice against lethal viral infection.
P2860
Q21090076-115BB4FD-05E1-4571-BA92-2A2C022F4DBEQ21562299-7C2481CD-351A-48C0-9D7A-72DBB5F9C2FBQ24655857-A1E1E8EA-6683-4341-8115-134555BD4B11Q24679494-7AED66CC-4D26-4D9E-BD1D-00970F234F75Q27012578-067C99F2-15D4-499A-A3B9-9E2ECC4B94D1Q27347652-5867F44C-3BBB-45E6-90A1-C2FE822FC45CQ27480835-66F04550-7A78-41AC-A688-EB3C961D4B27Q28296240-1EEE9A73-71D5-478B-8100-2804A1178E36Q30202358-34125F64-CF9A-4793-8128-F85754D9B269Q30328172-D8C7058C-823E-416A-BE23-95E54027D747Q30363581-D1E1453D-1DB2-413F-8DA5-DDB1428DBEAFQ30368221-7A4D96B2-6667-4F21-9C93-8A4546D73DB5Q30377017-EEA56548-E64D-4888-A420-D6190C36769FQ30384379-E77D131C-7240-456E-98A7-B4443492DF4BQ30403760-A495FD81-85A0-4349-8564-E4AD32EC38EEQ30418015-FA255C53-4C5F-4136-93A1-69B43CA86696Q30422513-666A6DFE-5EE7-47DC-AC70-053AC581C2B5Q30427778-F576D7C2-2BB0-42DB-9138-F2B5FD811B80Q33592225-75C0CF1A-AF41-499D-9DA6-048ABCFEF54FQ33683058-7751E09C-D890-4137-8860-D94D7F0B3FA1Q33834576-BE217DDC-697D-4735-A92C-A8BFBBF9E7E8Q33886452-0346F937-CCB5-4D17-9556-05EDF4F447E6Q34512592-E4762ED1-534A-42D7-AA5A-200FE24196E6Q34581910-F7FE274D-5011-427B-B39D-1378308BC59CQ34700580-07E56E6A-35FB-4C8A-8E81-A3119AF47EEFQ34854860-2CD77108-903E-4954-8121-C604AE5648E0Q35005641-5F17BDDF-7415-4D76-B921-8E0AD83BC4DBQ35489205-5318062E-9C73-4195-AC72-5EB8ABBE34F5Q35661214-083EA720-DCFF-4078-863B-449BFEC0E5EBQ35768825-BBA47CFA-6617-4939-84E7-B4491447B228Q35833488-7A312422-4E01-408A-A2FE-22B332A5C792Q35845659-ED94954A-FECE-41B3-9629-ABC4D03EBCEBQ35849627-0C51931A-3821-4A62-990D-FE978711B181Q35892324-7B05DBC4-FE07-4C83-8713-BF45524C1E82Q35947917-5A5E9A45-4758-4600-8D45-CBE125B2653BQ36276202-D50C43D6-6C67-4B6D-847F-716D86D6148AQ36345130-829F0A76-8E52-4FEE-B62C-89692B5FD061Q36349746-BFB3DBB6-1774-4B85-86C3-C0FCE475B4CEQ36401546-FDFA6257-7A19-4BD7-B8DF-E1BA93779628Q36446440-7989EAEC-BDDE-4AD3-8CA6-90B93D52AB33
P2860
Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh-hant
name
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@en
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@nl
type
label
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@en
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@nl
prefLabel
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@en
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@nl
P2093
P356
P1476
Cross-protection in mice infec ...... r cytotoxic T cell reactivity.
@en
P2093
P2860
P304
P356
10.1002/EJI.1830140414
P407
P577
1984-04-01T00:00:00Z